Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Lattanzi

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Vaccine|December 3, 2014
Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of ageMarkus Knuf, Geert Leroux-Roels, Hans C Rümke, et al.
Human Vaccines & Immunotherapeutics|June 9, 2026
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind studyAlejandro Hoberman, Jibran Atwi, Peter Silas, et al.
Travel Medicine and Infectious Disease|May 26, 2015
Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccineTomas Jelinek, Jakob P Cramer, Sebastian Dieckmann, et al.
Vaccine|May 26, 2012
A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populationsChristoph Hatz, Jakob P Cramer, André Vertruyen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 26, 2024
Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults Who Had Previously Received a Meningococcal ACWY Vaccine: A Phase 3, Randomized Controlled Clinical StudyTerry Nolan, Chiranjiwi Bhusal, Alejandro Hoberman, et al.
Annali Dell'Istituto Superiore Di Sanita|April 4, 2020
Social cognition deficit and genetic vulnerability to schizophrenia in 22q11 deletion syndromeMarianna Frascarelli, Gaia Padovani, Antonino Buzzanca, et al.
Science Translational Medicine|December 26, 2014
mTOR inhibition improves immune function in the elderlyJoan B Mannick, Giuseppe Del Giudice, Maria Lattanzi, et al.
Journal of Travel Medicine|March 21, 2016
One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary seriesJakob P Cramer, Tomas Jelinek, Maria Paulke-Korinek, et al.
Vaccine|September 5, 2020
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trialGeeta K Swamy, Torri D Metz, Kathryn M Edwards, et al.
Vaccine|March 15, 2020
Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trialJiri Beran, Geert Leroux-Roels, Pierre Van Damme, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Vaccine|December 3, 2014
Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of ageMarkus Knuf, Geert Leroux-Roels, Hans C Rümke, et al.
Human Vaccines & Immunotherapeutics|June 9, 2026
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind studyAlejandro Hoberman, Jibran Atwi, Peter Silas, et al.
Travel Medicine and Infectious Disease|May 26, 2015
Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccineTomas Jelinek, Jakob P Cramer, Sebastian Dieckmann, et al.
Vaccine|May 26, 2012
A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populationsChristoph Hatz, Jakob P Cramer, André Vertruyen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 26, 2024
Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults Who Had Previously Received a Meningococcal ACWY Vaccine: A Phase 3, Randomized Controlled Clinical StudyTerry Nolan, Chiranjiwi Bhusal, Alejandro Hoberman, et al.
Annali Dell'Istituto Superiore Di Sanita|April 4, 2020
Social cognition deficit and genetic vulnerability to schizophrenia in 22q11 deletion syndromeMarianna Frascarelli, Gaia Padovani, Antonino Buzzanca, et al.
Science Translational Medicine|December 26, 2014
mTOR inhibition improves immune function in the elderlyJoan B Mannick, Giuseppe Del Giudice, Maria Lattanzi, et al.
Journal of Travel Medicine|March 21, 2016
One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary seriesJakob P Cramer, Tomas Jelinek, Maria Paulke-Korinek, et al.
Vaccine|September 5, 2020
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trialGeeta K Swamy, Torri D Metz, Kathryn M Edwards, et al.
Vaccine|March 15, 2020
Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trialJiri Beran, Geert Leroux-Roels, Pierre Van Damme, et al.
Pageof 5